drugset / Trial / NCT02358187
A Vaccine Trial for Low Grade Gliomas
Phase 2
Recruiting
25 enrolled
James Felker
Connor's Cure · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The study will assess the immunogenicity, safety and preliminary clinical efficacy of the glioma associated antigen (GAA)/tetanus toxoid (TT) peptide vaccine and poly-ICLC in HLA-A2+ children with unresectable low-grade gliomas that have received at least two chemotherapy/biologic regimens. Radiation therapy counts as one biologic regimen, but patients may not have received radiation to the index lesion within 1 year of enrollment.
Timeline
- Start
- 2015-01
- Primary completion
- 2027-01-01
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC | Vaccine | — | Subcutaneous |
| Subject | Hiltonol | Other / unclassified | 30 ug/kg | Intramuscular |